The RealTime ready Influenza A/H1N1 Detection Set is used in conjunction with the RealTime ready RNA Virus Master kit also provided by Roche. The assay is carried out
Novartis has signed an agreement with Sarawak Biodiversity Centre (SBC) and BiotechCorp to discover bioactive compounds. Alexander Jetzer-Chung, director of Novartis said that the memorandum of understanding (MoU)
Galapagos has started a Phase II clinical study to evaluate Nanocort’s effectiveness in treating flares in multiple sclerosis (MS). Nanocort combines less frequent treatment with lower dosage and
Excluding the comparison of $57 million in fourth-quarter 2008 sales of oxycodone hydrochloride extended-release tablets (Oxy ER), fourth-quarter 2009 operational growth (net sales growth excluding the effect of
According to a warning letter dated August 12, 2009 and posted on November 17, 2009 on FDA’s Web site, FDA conducted an inspection at Abbott Molecular facility in
Microbix Biosystems has entered into a marketing and supply agreement with Riso Pharma for Kinlytic vials over the next three years. Kinlytic (Urokinase) is Microbix’ thrombolytic agent for
Alkermes has initiated phase 2 clinical study of Alks 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders.
YM BioSciences has presented preclinical results for Cyt997 at the Aacr-Nci-Eortc meeting Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The presentation was made by Cytopia. Cyt997
SIRO Clinpharm, a global contract research organization (CRO) has reported alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France. Chetan Tamhankar, chief
Appian Labs has entered an exclusive development and commercial license agreement for AppiForm Modular Release System with Capsugel. The agreement provides for Capsugel to utilise the AppiForm Modular
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.